Inhibition of oxidized LDL aggregation with the calcium channel blocker amlodipine: Role of electrostatic interactions

Atherosclerosis

Volumn 168, Issue 2, 2003, Pages 239-244

  Phillips, Jane Ellen ^a   Mason, R Preston ^b,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c 100 Cummings Center ^*  (United States)

Author keywords

Atherosclerosis; Modified lipoproteins; Phospholipid

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETHER DERIVATIVE; FELODIPINE; GLYCEROPHOSPHOLIPID; LIPID; LOW DENSITY LIPOPROTEIN; NIFEDIPINE; RAMIPRILAT; SEPHADEX; TRITIUM; VERAPAMIL;

ANTIATHEROSCLEROSIS ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG EFFECT; ELECTRICITY; EXTRACTION; IC 50; LIPID OXIDATION; LIPOPHILICITY; MEMBRANE BINDING; MEMBRANE MODEL; MEMBRANE VESICLE; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; PROTEIN AGGREGATION;

EID: 0037835467     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(03)00102-3     Document Type: Article

References (30)

1. Quinn M.T., Parthasarathy S., Fong L.G., Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA. 84:(9):1987;2995-2998.
2. Suits A.G., Chait A., Aviram M., Heinecke J.W. Phagocytosis of aggregated lipoprotein by macrophages: low density lipoprotein receptor-dependent foam-cell formation. Proc. Natl. Acad. Sci. USA. 86:1989;2713-2717.
3. Zhang W.Y., Gaynor P.M., Kruth H.S. Aggregated low density lipoprotein induces and enters surface-connected compartments of human monocyte-macrophages. J. Biol. Chem. 272:1997;31700-31706.
4. Frostegard J., Haegerstrand A., Gidlund M., Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis. 90:(2-3):1991;119-126.
5. Schwartz C.J., Valente A.J., Sprague E.A., Kelley J.L., Nerem R.M. The pathogenesis of atherosclerosis: an overview. Clin. Cardiol. 14:(2 Suppl 1):1991;I1-I16.
6. Cathcart M.K., Morel D.W., Chisolm G.M. III. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J. Leukoc. Biol. 38:(2):1985;341-350.
7. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 84:1987;7725-7729.
8. Sasahara M., Raines E.W., Chait A., et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation. J. Clin. Invest. 94:(1):1994;155-164.
9. Belcher J.D., Balla J., Balla G., et al. Vitamin E, LDL, and endothelium. Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro. Arterioscler. Thromb. 13:(12):1993;1779-1789.
10. Cote G., Tardif J.-C., Lesperance J., et al. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation. 99:1999;30-35.
11. 2+ channel blockers to the membrane lipid bilayer. Mol. Pharmacol. 41:(2):1992;315-321.
12. Mason R.P., Campbell S.F., Wang S.D., Herbette L.G. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol. Pharmacol. 36:(4):1989;634-640.
13. Bauerle H.D., Seelig J. Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes. Binding equilibrium, binding enthalpy, and membrane location. Biochemistry. 30:(29):1991;7203-7211.
14. Mason R.P., Walter M.F., Trumbore M.W., Olmstead E.G. Jr., Mason P.E. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J. Mol. Cell Cardiol. 31:1999;275-281.
15. Tulenko T.N., Laury-Kleintop L., Walter M.F., Mason R.P. Cholesterol, calcium and atherosclerosis: Is there a role for calcium channel blockers in atheroprotection? Int. J. Cardiol. 62:(Suppl 2):1997;55S-66S.
16. Byingyton R., Riley W., Booth D., et al. Effect of amlodipine on progression of carotid atherosclerosis in patients with documented heart disease. Am. J. Hypertens. 12:1999;42A-43A.
17. Pitt B., Byingyton R.P., Furberg C.D., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 102:2000;1503-1510.
18. Tulenko T.N., Chen M., Mason P.E., Mason R.P. Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J. Lipid Res. 39:1998;947-956.
19. Kellner-Weibel G., Yancey P.G., Jerome W.G., et al. Cystallization of free cholesterol in model macrophage foam cells. Arterioscler. Thromb. Vasc. Biol. 19:1999;1891-1898.
20. Rodrigueza W.V., Wheeler J.J., Klimuk S.K., Kitson C.N., Hope M.J. Transbilayer movement and net flux of cholesterol and cholesterol sulfate between liposomal membranes. Biochemistry. 34:1995;6208-6217.
21. Phillips J.E., Rodrigueza W.V., Johnson W.J. Basis for rapid efflux of biosynthetic desmosterol from cells. J. Lipid Res. 39:1998;2459-2470.
22. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol Biol. 13:1965;238-252.
23. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:(14):1989;915-924.
24. Steinbrecher U.P., Lougheed M., Kwan W.C., Dirks M. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J. Biol. Chem. 264:(26):1989;15216-15223.
25. Frostegard J., Nilsson J., Haegerstrand A., Hamsten A., Wigzell H., Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc. Natl. Acad. Sci. USA. 87:(3):1990;904-908.
26. Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 343:1990;531-535.
27. Rohrer L., Freeman M., Kodama T., Penman M., Krieger M. Coiled-coil fibrous domains mediate ligand binding by macrophage scavenger receptor type II. Nature. 343:1990;570-572.
28. Waters D., Lesperance J., Francetich M., et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 82:1990;1940-1953.
29. Lichtlen P.R., Hugenholtz P.G., Rafflenbeul W., Hecker H., Jost S., Deckers J.W. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine trial on Antiatherosclerotic Therapy (INTACT). Lancet. 335:1990;1109-1113.
30. Borhani N.O., Mercuri M., Borhani P.A., et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA. 276:(10):1996;785-791.